Nivolumab,Relatlimab
BMS
['melanoma']
caught a great presentation from #sitc member from with updated results from the relativity-47 trial for melanoma at #asco23. #melanoma 
Society for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.